Indevus Sanctura XR To Begin Phase III Trials “Shortly”

Firm targets second half of 2006 for NDA submission for the extended-release formulation of the overactive bladder treatment. Sanctura maintains 3% share of new prescriptions in the quarter despite heavy promotion from competitors.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet